Annals of Oncology APC and Open Access: Current ESMO Pricing, Agreement Rules, and When Gold OA Is Worth It

The current ScienceDirect OA page for Annals of Oncology is unusually clear:

• the journal offers both open access and subscription
• the Article Publishing Charge (APC) is EUR 5,556 excluding taxes
• subscription articles carry no open-access publication fee
• accepted manuscripts can be self-archived immediately
• public release from the institutional repository follows a 12-month embargo

That matters because older Annals APC pages often rely on a dollar range. The current official page is cleaner than that. The journal now exposes a single published APC in euros for all article types under the OA route.

The same page also says Elsevier's pricing system offers the lowest possible APC based on the author's context, including country, affiliation, and agreement status. So while EUR 5,556 is the published sticker price, the actual amount can be lower when an agreement or country-based reduction applies.

This is the real value proposition. Annals of Oncology is not charging a premium fee on a mid-tier oncology journal. It is charging a premium fee on one of the most influential clinical-oncology journals in the world, especially for major trial data, guideline-shaping evidence, and translational papers with direct treatment consequence.

The direction is sharply positive. Annals of Oncology is up from 56.4 in 2023 to 65.4 in 2024. That is not a normal plateau pattern. It means the journal is still gaining citation strength while many peer journals have already normalized downward.

This is the practical planning rule:

• if your funder requires the final version of record to be open immediately, the APC matters
• if your real need is repository compliance after embargo, the free route is already defined

For Annals of Oncology, that distinction matters because many authors reach the right oncology audience even on the subscription route. ESMO members, major cancer centers, and academic medical libraries already cover most of the clinical-oncology core readership.

In our pre-submission review work, the expensive mistake is usually not the APC itself. The expensive mistake is treating Annals of Oncology as if its editorial bar were only about "good clinical oncology."

What usually works:

• practice-changing trial or outcomes data
• translational work with obvious consequence for oncology decisions
• manuscripts that read like ESMO-level evidence, not just strong specialty evidence

What usually creates regret:

• interesting oncology studies that are still too local or too incremental
• translational or biomarker papers without enough clinical consequence
• deciding on gold OA before the editorial-fit question is honestly answered

The journal's own process guidance reinforces this. Manuscripts of insufficient priority are often returned quickly, while strong papers that clear triage face a more selective multi-week review path.

For Annals of Oncology APC, the current answer is cleaner than many older summaries:

• official APC: EUR 5,556
• subscription route: free
• green route: accepted manuscript can be archived immediately, public after 12 months

That means the right sequence is:

1. confirm the paper is actually Annals-grade
2. check agreement or funder coverage
3. decide whether the final published version really needs immediate OA